On June 9, 2026, China’s Supreme People’s Court issued the Guidelines for Ascertaining Technical Facts in Cases Involving New Plant Varieties (人民法院审理植物新品种案件技术事实查明工作指引) (the “Guidelines”). The Guidelines represent the first dedicated instrument governing the ascertainment of technical facts in plant variety rights litigation in China, and were promulgated pursuant to the Civil Procedure Law of the People’s Republic of China, the Seed Law of the People’s Republic of China, and the Regulations on the Protection of New Plant Varieties, among other …
Category: New Law, Rule or Implementing Regulation
China’s National Intellectual Property Administration Publishes 2026 Plan for Building a Strong Intellectual Property Nation
On May 16, 2026, China’s National Intellectual Property Administration (CNIPA) published the 2026 Plan for Building a Strong Intellectual Property Nation (2026年知识产权强国建设推进计划). The Plan is an annual implementation document released by the Office of the Inter-Ministerial Joint Conference on Building a Strong Intellectual Property Nation. It operationalizes the longer-term Outline for Building a Strong Intellectual Property Nation (2021–2035) by setting out the specific intellectual property tasks to be undertaken across Chinese government ministries, agencies, and judicial bodies during the 2026 …
China’s National Medical Products Administration Releases Interpretation of the “Implementation Measures for the Measures for Drug Trial Data Protection”
In follow up to the May 15, 2026 release of the Implementation Measures for the Measures for Drug Trial Data Protection (药品试验数据保护实施办法), China’s National Medical Products Administration also released an Interpretation of the same. The Interpretation provides more details on the Measures, such as what is test data used to prove the safety, efficacy and quality controllability of drugs and is new clinical trial data protected for conditionally approved drugs.
China’s National Medical Products Administration Releases Implementation Measures for Drug Trial Data Protection – May 30, 2026 Submission Deadline!
May 20, 2026 Update: As pointed out by Fan Li, the Center for Drug Evaluation (CDE) subsequently released a Notice clarifying that the deadline for retroactive protection is 15 working days from the May 15 NMPA release yielding a deadline of June 5, 2026. On May 15, 2026, China’s National Medical Products Administration (NMPA) released the Implementation Measures for Drug Trial Data Protection (药品试验数据保护实施办法), effective May 15, 2026. The Measures provide equal drug trial data protection terms for domestic and foreign-developed drugs. …